Skip to content
Premier Weight Loss Indianapolis
Dual GIP/GLP-1 Receptor Agonist

Dual-Action Weight Loss with Blood Sugar Control

Mounjaro® (Tirzepatide)Mounjaro® (tirzepatide) is a revolutionary dual-action medication that targets both GIP and GLP-1 receptors for powerful weight loss and blood sugar management.

Program Details
  • Avg weight loss

    20-22%

  • vs retail

    75%

    up to 75% savings

  • Frequency

    Once Weekly

GLP-1 medications are priced separately: Ozempic starts at $175/month and Zepbound starts at $275/month, up to 75% less than retail pharmacy prices.

How Mounjaro works

Tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism enhances insulin secretion, reduces glucagon, slows gastric emptying, and significantly decreases appetite. The combined effect creates a powerful metabolic shift that helps patients lose substantially more weight than single-receptor medications.

Clinical evidence

In the SURMOUNT-1 trial, patients taking the highest dose of tirzepatide lost an average of 22.5% of their body weight over 72 weeks.

Benefits at PWL

  • Industry-leading 20-22% average body weight loss
  • Dual GIP/GLP-1 mechanism for enhanced results
  • Once-weekly self-administered injection
  • Significantly reduces appetite and cravings
  • Excellent blood sugar control for diabetics
  • May improve cardiovascular risk factors
  • Helps preserve lean muscle mass
  • Reduces inflammation markers

Common side effects

  • Nausea (usually temporary, improves after 2-4 weeks)
  • Diarrhea or constipation
  • Decreased appetite (expected therapeutic effect)
  • Injection site reactions (mild redness)
  • Acid reflux or indigestion

Side effects are typically mild and improve over time. Your provider guides you on managing any symptoms during your monthly check-ins.

Important Considerations

Who Should Not Take Mounjaro

  • Personal history of pancreatitis
  • Personal or family history of medullary thyroid cancer (MTC)
  • Personal or family history of multiple endocrine neoplasia type 2 (MEN2)
  • Pregnant or breastfeeding patients
  • Patients with severe gastrointestinal motility disorders, with case-by-case provider review

Black Box Warning

Tirzepatide causes thyroid C-cell tumors in rodents. It is not known whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should be counseled regarding the potential risk of MTC and symptoms of thyroid tumors.

Medically reviewed by Dr. Scott Friedman, MD ·

FAQ

Common Questions About Mounjaro

  • How much weight can I lose with Mounjaro?

    Clinical trials (SURMOUNT for Zepbound, SURPASS for Mounjaro) showed average weight loss of 20-22% with tirzepatide. For someone starting at 250 lbs, that is approximately 50-55 pounds. Individual results vary based on starting weight, adherence, dose, and lifestyle factors.

  • What are the most common Mounjaro side effects?

    Nausea, mild GI changes, constipation, fatigue, and occasional acid reflux are most common, especially during the first few weeks and after dose increases. Most side effects are mild and resolve with dose adjustment, hydration, increased fiber and protein, and time. Your provider monitors closely throughout treatment.

  • Is Mounjaro brand-name or compounded?

    Premier Weight Loss prescribes only brand-name, FDA-approved Mounjaro. We never use compounded alternatives. All medication arrives in original manufacturer packaging.

  • How much does Mounjaro cost at Premier Weight Loss?

    Mounjaro starts at $275/month at Premier Weight Loss, up to 75% less than retail pharmacy prices. Final pricing depends on dose and is confirmed with your provider during the consultation.

  • How is Mounjaro different from the other GLP-1s you prescribe?

    Mounjaro (tirzepatide) is a dual-action medication that activates both GIP and GLP-1 receptors, which is why trial weight loss is higher than semaglutide (Wegovy, Ozempic). Your provider will recommend the best option based on your goals, health profile, and treatment response.

Ready to start with Mounjaro?

Reserve a $45 consult. Your provider will confirm the right medication and dose for you.